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Aims: To evaluate whether 2 years of treatment with bisphosphonates in combina-
tion with calcium/vitamin D supplements has an effect on lumbar spine and hip bone
mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis
factor-α inhibitors or receiving conventional treatment. Secondly, to explore the
development of radiographic vertebral fractures.
Methods: Patients from the Groningen Leeuwarden AS cohort receiving
bisphosphonates based on clinical indication and available 2-year follow-up BMD
measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal
femur) were measured using dual-energy X-ray absorptiometry. Spinal radiographs
(Th4–L4) were scored for vertebral fractures according to the Genant method.
Results: In the 20 included patients (median 52 years, 14 males), lumbar spine and
hip BMD Z-scores increased significantly; median from −1.5 (interquartile range
[IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P < .001 and median from −1.0 (IQR −1.6
to −0.7) to −0.8 (IQR −1.2 to 0.0); P = .006 over 2 years, respectively. In patients also
treated with tumour necrosis factor-α inhibitors (n = 11), lumbar spine and hip BMD
increased significantly (median 2-year change +8.6% [IQR 2.4 to 19.6; P = .009] and
+3.6% [IQR 0.7–9.0; P = .007]). In patients on conventional treatment (n = 9), lumbar
spine BMD increased significantly (median 2-year change +3.6%; IQR 0.7 to 9.0;
P = .011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to
5.1; P = .61). Overall, younger AS males with limited spinal radiographic damage
showed most improvement in lumbar spine BMD. Four mild radiographic vertebral
fractures developed in 3 patients and 1 fracture increased from mild to moderate
over 2 years in postmenopausal women and middle-aged men.
Conclusion: This explorative observational cohort study in AS showed that 2 years
of treatment with bisphosphonates in combination with calcium/vitamin D supple-
ments significantly improves lumbar spine BMD. Mild radiographic vertebral frac-
tures still occurred.
The authors confirm that the PI for this paper is Dr. Anneke Spoorenberg and that she had
direct clinical responsibility for patients.
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1 | INTRODUCTION
Ankylosing spondylitis (AS) is a chronic rheumatic inflammatory dis-
ease, which mainly affects the axial skeleton. Besides spinal
osteoproliferation, excessive bone loss is a major complication of
AS. Low bone mineral density (BMD), especially at the lumbar spine,
can already be observed at a relatively young age.1,2 Acute inflamma-
tory lesions on sacroiliac joint magnetic resonance imaging were
found to be associated with low BMD.3 Vertebral fractures are the
most important outcome of excessive bone loss and are frequently
present in AS patients.1,4
The main cause of primary osteoporosis is age-related bone
loss in postmenopausal women. Secondary osteoporosis results
from the presence of other diseases or conditions that predisposes
to bone loss and occurs in both males and females. Currently, there
are no clear guidelines for the evaluation of bone loss and the
treatment of secondary osteoporosis in patients with AS. In daily
clinical practice, secondary osteoporosis is often treated according
to the same guidelines as primary osteoporosis, although AS mainly
affects males at relatively young age. This antiosteoporotic treat-
ment consists of bisphosphonates in combination with cal-
cium/vitamin D supplements.
Several studies in AS investigated the anti-inflammatory effect of
bisphosphonates.5–10 However, follow-up data regarding the effect of
bisphosphonates on BMD are scarce and data about the effect on
vertebral fractures are lacking. There is 1 open-label study in AS
patients with active disease that showed a significant improvement in
absolute BMD scores at the lumbar spine after 6 months of treatment
with neridronate, which was not observed at the hip.8 Another retro-
spective study in AS patients with spinal pain intensity score >4 (on a
scale of 0–10) did not show beneficial effect on lumbar spine or hip
BMD after 6 months treatment with alendronate.11
Nowadays, tumour necrosis factor-α (TNF-α) inhibitors are pre-
scribed to control disease activity, with good long-term adherence in
daily clinical practice.12 These agents also have proven to have an
effect on BMD. A large randomized controlled trial found a significant
increase in BMD at the lumbar spine and hip after 6 months of
infliximab compared with placebo. Open-label extension showed fur-
ther improvement in BMD after 2 years of infliximab.13 Multiple
observational studies reported a continuous improvement in BMD at
the lumbar spine and, to a lesser extent, at the hip after long-term
treatment withTNF-α inhibitors.1,14
The aim of the present study was to evaluate whether 2 years of
treatment with bisphosphonates in combination with calcium/vitamin
D supplements has an effect on lumbar spine and hip BMD in AS
patients starting TNF-α inhibitors or receiving conventional treatment
in daily clinical practice. Secondly, to explore the development of
radiographic vertebral fractures in these patients.
2 | METHODS
The Groningen Leeuwarden AS (GLAS) cohort is an ongoing prospec-
tive observational cohort study which started at the end of 2004 in
the north of the Netherlands (principal investigator: Dr
A. Spoorenberg). For the present analysis, patients fulfilling the modi-
fied New York criteria for AS, who were treated with bisphosphonates
in combination with calcium and/or vitamin D supplements and had
available 2-year follow-up BMD measurements were included. The
antiosteoporotic treatment was started based on clinical indication
according to the treating physician.
The GLAS cohort was approved by the local ethics committees of
the Medical Center Leeuwarden (MCL) and University Medical Center
Groningen (UMCG). All patients provided written informed consent
according to the Declaration of Helsinki.
What is already known about this subject
• Osteoporosis and vertebral fractures occur in hip anky-
losing spondylitis (AS) patients at relatively young age.
• In daily clinical practice, treatment with bisphosphonates
is often applied in AS, but scientific studies with
>6 months follow-up regarding the effect on bone min-
eral density (BMD) and vertebral fractures are lacking.
What this study adds
• Lumbar spine BMD improved significantly during 2 years
of bisphosphonates, which was most pronounced in
younger AS males with limited spinal radiographic
damage.
• Hip BMD only improved significantly in patients also
treated with tumour necrosis factor-α inhibitors.
• Mild radiographic vertebral fractures still occurred in
postmenopausal women and middle-aged men. Most
fractures were observed in patients who already had ver-
tebral fractures and who were also treated with tumour
necrosis factor-α inhibitors because of persistent active
disease.
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2.1 | Assessments of bone loss
2.1.1 | BMD
At first visit and after 2 years of follow-up, BMD at the lumbar spine
(anterior–posterior projection at L1–L4) and hip (total proximal femur)
were measured using the same dual-energy X-ray absorptiometry
machine within patients (Hologic QDR Discovery for UMCG patients
and Hologic QDR Delphi for MCL patients, Waltman, MA, USA). Coef-
ficient of variation (CV) and least significant change were evaluated
automatically using Hologic software. CV for total BMD was reported
to be 1.0%, least significant change was reported to be 0.022 g/cm2
for lumbar spine BMD and 0.027 g/cm2 for hip BMD. Lumbar verte-
brae showing fractures were excluded from the BMD measurement.
Z-scores, the number of standard deviations from the normal mean
corrected for age and sex, were calculated using the NHANES refer-
ence database. The International Society for Clinical Densitometry
recommends using BMD Z-scores instead of BMD T-scores in
premenopausal women and men younger than 50 years.15
2.1.2 | Vertebral fractures
Lateral radiographs of the thoracic and lumbar spine were scored for
radiographic vertebral fractures by 2 independent readers blinded for
patient characteristics.4 According to the method of Genant et al.,
anterior, middle and posterior heights of the vertebra Th4–L4 were
assessed. Fractures were categorized as mild (≥20–<25% height
reduction), moderate (≥25–<40% height reduction) or severe (≥40%
height reduction).
2.2 | Other assessments
At the same time points, serum levels of 25-hydroxyvitamin D
(25OHvitD) were measured by radioimmunoassay (DiaSorin,
Stillwater, MN, USA; inter assay coefficient of variation IE-CV) 14–
15%; UMCG until June 2010 and MCL until July 2008), ECLIA
(Modular Analytics E170, Roche Mannheim, Germany; IE-CV
12–13%; MCL July 2008 until 2011), or automated liquid chromatog-
raphy–mass spectrometry method (IE-CV 4–5%; UMCG since 2010
and MCL since 2011). Disease activity was assessed using AS disease
activity score, Bath AS disease activity index and C-reactive protein
(measured during routine diagnostic patient care; IE-CV < 5%). Lateral
radiographs of the cervical and lumbar spine were scored for spinal
radiographic damage by 2 independent readers using the modified
Spine AS score (mSASSS).4
2.3 | Statistical analysis
Results were expressed as number of patients (%) or median (inter-
quartile range [IQR]) for categorical and continuous data, respectively.
Fisher's Exact and Mann–Whitney U tests were used to compare
patient characteristics between groups. Wilcoxon-signed rank test
was used to compare assessments at first visit and after 2 years of
follow-up. Analyses were stratified for starting treatment with TNF-α
inhibitors or receiving conventional treatment (nonsteroidal anti-
inflammatory drugs). P-values ≤0.05 were considered as statistically
significant. Statistical analysis was performed with IBM SPSS Statistics
23 (SPSS, Chicago, IL, USA).
3 | RESULTS
Of the 20 included AS patients, 11 were treated with risedronate
(35 mg/wk), 7 with alendronate (70 mg/wk), 1 with intravenous
pamidronate (60 mg) and 1 with etidronic acid–calcium carbonate. In
the majority of patients, antiosteoporotic treatment was started
because of osteoporosis. Other reasons were systemic steroid use or
the presence of osteopenia and vertebral fractures. Eleven (55%)
patients started TNF-α inhibitors because of active disease (10 contin-
ued this treatment for 2 y) and the other 9 (45%) received conven-
tional treatment for AS symptoms. Patient characteristics at first visit
and type of bisphosphonate used in both treatment groups are pres-
ented inTable 1.
Seventeen (85%) patients used bisphosphonates during the entire
2-year follow-up within the GLAS cohort (TNF-α inhibitor group:
n = 9, conventional treatment group: n = 8). Thirteen (65%) patients
started treatment with bisphosphonates median 3.1 years before
inclusion in the GLAS cohort (TNF-α inhibitor group: n = 9, median
3.1 y, conventional treatment group: n = 4, median 3.8 y).
As expected, all disease activity assessments were significantly
higher in patients starting TNF-α inhibitors. Furthermore, physical
function was worse and serum levels of 25-hydroxyvitamin D were
lower. Disease severity expressed by spinal radiographic damage
(mSASSS) was similar in both treatment groups. Also lumbar spine and
hip BMD were comparable between both groups, although radio-
graphic vertebral fractures were more often found in patients starting
TNF-α inhibitors.
3.1 | Change in BMD over 2 years
In the total group, treatment with bisphosphonates in combination
with calcium/vitamin D supplements significantly improved lumbar
spine and hip BMD; median lumbar spine BMD Z-score increased
from −1.5 at first visit to 0.1 after 2 years (P < .001) and median hip
BMD Z-score from −1.0 at first visit to −0.8 after 2 years (P = .006).
Similar results were found for BMD T-scores (data not shown).
In the 11 patients starting TNF-α inhibitors, lumbar spine BMD
increased significantly (Figure 1A); median change in Z-score was
0.7 (IQR 0.3 to 1.4) and in absolute BMD 8.6% (IQR 2.4 to 19.6).
Also hip BMD increased significantly (Figure 1B); median change in
Z-score was 0.3 (IQR 0.2 to 0.6) and in absolute BMD 3.6% (IQR
1.5 to 7.8).
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In the 9 patients on conventional treatment, lumbar spine BMD
increased significantly (Figure 1C); median change in Z-score was 0.4
(IQR 0.2 to 0.7) and in absolute BMD 3.6% (IQR 0.7 to 9.0). No signifi-
cant improvement in hip BMD was found (Figure 1D); median change
in Z-score was 0.1 (IQR −0.2 to 0.3) and in absolute BMD −0.6% (IQR
−3.1 to 5.1).
Overall, improvement in lumbar spine BMD of ≥0.5 Z-score was
found in males (82%) of relatively young age (median 45 years) and
limited spinal radiographic damage (median 4.3 mSASSS units).
3.2 | Development of vertebral fractures
During 2-year follow-up, 4 new radiographic vertebral fractures
were found in 3 of the 17 (18%) patients. In patients with TNF-α
inhibitors, 3 mild fractures occurred in 2 postmenopausal females
(67 and 68 years). In addition, 1 existing fracture increased in sever-
ity from mild to moderate in 1 male (48 years). In patients on con-
ventional treatment, 1 new mild fracture was observed in 1 male
(51 years). None of these fractures received clinical attention. More
TABLE 1 Characteristics of the AS study population treated with bisphosphonates in combination with calcium/vitamin D supplements,
stratified for the use of TNF-α inhibitors
All patients
(n = 20)
Patients starting TNF-α inhibitors
(n = 11)
Patients on conventional treatment
(n = 9)
Male sex 14 (70) 7 (64) 7 (78)
Age (y) 52 (46 to 64) 57 (45 to 65) 50 (46 to 61)
Duration of symptoms (y) 27 (8 to 40) 20 (8 to 44) 29 (15 to 39)
Time since diagnosis (y) 7 (4 to 28) 8 (5 to 28) 6 (1 to 31)
HLA-B27+ 15 (75) 6 (55) 9 (100)*
NSAID use 13 (65) 5 (46) 8 (89)
Systemic steroid use 3 (15) 1 (9)' 2 (22)
00
ASDASCRP 3.6 (2.2 to 4.4) 4.2 (3.5 to 4.6) 2.1 (1.8 to 3.5)
*
BASDAI (range 0–10) 5.3 (2.8 to 7.3) 5.8 (5.0 to 8.0) 3.8 (1.9 to 5.5)*
CRP (mg/l) 15 (4 to 23) 19 (10 to 24) 5 (2 to 15)*
BASFI (range 0–10) 7.2 (3.8 to 7.9) 7.6 (7.1 to 8.5) 3.9 (1.3 to 7.3)*
LS BMD Z-score −1.5 (−2.2 to 0.4) −0.8 (−2.3 to 0.6) −1.6 (−2.8 to 0.0)
LS BMD Z-score ≤−1 10 (53) 5 (50) 5 (56)
LS BMD Z-score ≤−2 6 (32) 3 (30) 3 (33)
Hip BMD Z-score −1.0 (−1.6 to −0.7) −1.0 (−1.8 to −0.8) −1.0 (−1.5 to 0.1)
Hip BMD Z-score ≤−1 11 (58) 7 (64) 4 (50)
Hip BMD Z-score ≤−2 1 (5) 1 (9) 0 (0)
25OHvitD (nmol/L) 66 (36 to 89) 38 (29 to 70) 89 (55 to 96)*
Radiographic VFa 7 (41) 6 (60)† 1 (14)‡
mSASSS (range 0–72)b 6.0 (2.9 to 42.3) 14.2 (3.4 to 33.7) 5.2 (1.6 to 63.2)
Type of bisphosphonate treatment
Risedronate 11 (55) 6 (55) 5 (56)
Alendronate 7 (35) 3 (27) 4 (44)
Intravenous pamidronate 1 (5) 1 (9) 0 (0)
Etidronic acid-calcium
carbonate
1 (5) 1 (9) 0 (0)
Values are number (%) of patients or median (interquartile range).
aRadiographs of the thoracic and lumbar spine could be scored in 17 patients. b Radiographs of the cervical and lumbar spine could be scored in 14
patients.
*P < .05 compared to patients starting TNF-α inhibitors.
'prednison (5 mg/d);
00
budenofalk (3 and 6 mg/d).
†16 vertebral fractures (9 mild, 5 moderate, 2 severe) in 6 patients;
‡1 vertebral fracture (mild) in 1 patientAS: ankylosing spondylitis; TNF-α: tumour necrosis factor-α; HLA-B27+: human leukocyte antigen B27 positive;
ASDAS: AS disease activity score; BASDAI: Bath AS disease activity index; CRP: C-reactive protein; BASFI: Bath AS functional index; LS: lumbar spine;
BMD: bone mineral density; 25OHvitD: 25-hydroxyvitamin D; VF: vertebral fracture; mSASSS: modified stoke AS spinal score; NSAID, nonsteroidal
anti-inflammatory drug.
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details about the characteristics and treatment of these patients are
presented in Table 2.
3.3 | Other assessments over 2 years
There was no significant change in serum levels of 25-hydroxyvitamin
D over 2 years (Table 3). Disease activity decreased significantly in
both groups; median improvement in AS disease activity score was
2.1 for patients starting TNF-α inhibitors and 0.4 for patients on con-
ventional treatment. Overall, spinal radiographic progression was rela-
tively low. Median progression in mSASSS was 1.4 (IQR 0.5 to 1.6)
and 0.0 (IQR 0.0 to 0.4) in these 2 treatment groups, respectively.
Two patients developed 1 new syndesmophyte in the TNF-α inhibitor
group compared to none in the conventional treatment group.
4 | DISCUSSION
The present study evaluated whether 2 years of treatment with
bisphosphonates in combination with calcium/vitamin D supplements
has an effect on lumbar spine and hip BMD in established AS patients
from daily clinical practice. BMD improved significantly during treat-
ment with bisphosphonates, as was shown in other small studies.8,16
The median change in absolute BMD scores after 2 years of
bisphosphonates was +8.6 and +3.6% at the lumbar spine and +3.6
F IGURE 1 Lumbar spine and hip bone mineral density (BMD) Z-scores during 2 years of treatment with bisphosphonates in combination with
calcium/vitamin D supplements in 20 ankylosing spondylitis patients, stratified for the use of tumour necrosis factor-α inhibitors. GLAS,
Groningen Leeuwarden ankylosing spondylitis
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and −0.6% at the hip, respectively, in patients starting treatment with
TNF-α inhibitors or receiving conventional treatment. Interestingly, in
both groups, most improvement in lumbar spine BMD was found in
younger males with limited spinal radiographic damage. Previously, a
retrospective cohort study compared BMD change over approxi-
mately 1-year in 4 groups of AS patients on conventional treatment
(n = 40), bisphosphonates plus conventional treatment (n = 20), TNF-α
inhibitors (n = 19) and bisphosphonates plus TNF-α inhibitors (n = 11).
They reported that BMD improvement at the greater trochanter of
the hip was most pronounced in patients receiving bisphosphonates
in combination with TNF-α inhibitors.16 An open-label study including
AS patients with active disease (Bath AS disease activity index ≥4)
investigated BMD as secondary outcome during 6 months of treat-
ment with high intravenous doses of the amino-bisphosphonate
neridronate (n = 30) or infliximab (n = 30). In line with our findings,
they showed that bisphosphonates resulted in a significant increase in
absolute BMD scores at the lumbar spine (mean improvement 4.3%),
but not at the hip (mean improvement 0.1–2.2%).8 In contrast to our
and other studies with TNF-α inhibitors,12,16–18 they reported that
infliximab had no significant effect on BMD. Unfortunately, no further
analysis or discussion was provided. Supporting our data and those of
other studies, a meta-analysis including 568 AS patients from 1 ran-
domized controlled trial and 7 observational studies consistently
demonstrated that lumbar spine and total hip BMD increased signifi-
cantly with 8.6 and 2.5%, respectively, after 2 years of treatment with
TNF-α inhibitors.14
Bisphosphonates and TNF-α inhibitors influence the bone metab-
olism differently. Bisphosphonates have an inhibitory effect on bone
resorption by chemical adsorption to hydroxyapatite and/or a direct
effect on osteoclast activity.19,20 The underlying pathophysiological
mechanism of TNF-α inhibitors on the bone metabolism is not yet
completely understood, but most likely involves the Wnt signaling
pathway, which affects both osteoclasts and osteoblasts activity.21 A
recent cross-sectional study including 71 AS patients showed that
higher serum levels of Dickkopf-1, a natural inhibitor of the Wnt path-
way, were associated with lower lumbar spine BMD and prevalent
radiographic vertebral fractures. This indicates that high levels of
Dickkopf-1 are related to the severity of bone loss in AS.22
Besides the effect of bisphosphonates on BMD, we also explored
the development of radiographic vertebral fractures, the most
important clinical outcome reflecting bone loss of the spine. At first
visit, 17 mild to severe vertebral fractures were found in 7 (41%)
patients. During 2 years, 4 mild vertebral fractures developed in
3 (18%) patients and 1 existing fracture increased from mild to moder-
ate. The majority of prevalent and incident vertebral fractures were
found in patients with active disease, starting treatment with TNF-α
inhibitors. This can probably be explained by persistently high disease
activity (before the start of TNF-α inhibitors), lower serum levels of
vitamin D and worse physical function in these AS patients. New
radiographic vertebral fractures occurred in postmenopausal women
and middle-aged men. Three out of these 4 patients already had mul-
tiple vertebral fractures.
The present study is the first to explore the development of ver-
tebral fractures in AS patients with a clinical indication for
antiosteoporotic treatment. In our larger observational study on verte-
bral fractures, 39 (21%) of the 184 AS patients starting TNF-α inhibi-
tors already had radiographic vertebral fractures at baseline, 9 (5%)
developed new vertebral fractures and 7 (4%) showed an increase in
severity of existing factures after 2 years of follow-up.4 Another
observational study in 49 AS patients starting etanercept reported
that the number of patients with radiographic vertebral fractures
increased from 6 (12%) at baseline to 15 (31%) after 2 years.23
For the present analysis, we selected patients who were treated
with bisphosphonates and had available 2-year follow-up BMD mea-
surements. As expected, this subgroup of patients was older
(median 52 vs 43 y), had longer duration of AS symptoms (median
TABLE 2 Characteristics and treatment of AS patients with new vertebral fractures (n = 3) or increase in severity (n = 1) during 2 years of
follow-up
Patient 1 Patient 2 Patient 3 Patient 4
Development of VF + site New: Th12 and L3 grade 1,
biconcave
New: Th12 grade 1, biconcave Increase in severity: Th11
grade 2, wedge
New: Th8 grade 1,
biconcave
Sex, age Female, 67 y Female, 67 y Male, 48 y Male, 51 y
Bisphosphonate
treatment, % of time
used
Pamidronate 60 mg/12 wk,
100%





Anti-TNF treatment, % of
time used
Adalimumab 40 mg/2 wk,
84% (stopped)
Etanercept 50 mg/wk, 100% Infliximab, 300 mg/8 wk,
100%
No
Presence of VF at
baseline + site
Th9, Th10 grade 2, Th11
grade 3, biconcave
Th7 grade 1, wedge, Th9 grade 2,
Th11 grade 3, biconcave
Th9, Th10, Th11, Th12
grade 1, wedge
No
BMD LS Z-score baseline
vs 2 y
N/A −2.2 vs 0.1 −2.5 vs -1.5 −1.8 vs -1.1
BMD hip Z-score baseline
vs 2 y
−0.9 vs 0.0 −1.9 vs -1.6 −1.8 vs -1.6 −1.2 vs -1.1
ASDAS baseline vs 2 y 4.41 vs 3.82 3.52 vs 2.72 4.60 vs 2.26 1.87 vs 1.42
SeeTable 1 for abbreviations
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27 vs 16 y), lower BMD (median lumbar spine Z-score −1.5 vs −0.4,
hip Z-score −1.0 vs −0.2) and more often radiographic vertebral
fractures (41 vs 20%) in comparison with the total study population
from the GLAS cohort.4
The present study is based on real life data. The antiosteoporotic
treatment was started based on clinical indication according to the
treating physician, mainly the presence of osteoporosis. Unfortu-
nately, the Fracture Risk Assessment Tool score was not yet available
in these patients. A limitation of our study is that the effect of
bisphosphonates on BMD may be underestimated since 65% of the
patients started treatment with bisphosphonates before inclusion in
the GLAS cohort (median 3.1 y). An open-label extension study in
postmenopausal women showed that continuous alendronate treat-
ment for 7 years increased BMD, but the largest increase was
observed during the first 3 years of treatment.24
It is known that the anterior–posterior view of the lumbar spine
DXA can be overestimated by the presence of syndesmophytes.25,26
Since mSASSS progression was relatively low and the large majority
of patients did not develop new syndesmophytes over 2 years, it can
be assumed that there was no influence of spinal osteoproliferation
on the 2-year improvement in lumbar spine BMD. Moreover, young
AS males with limited spinal radiographic damage showed most
improvement in lumbar spine BMD. We do realize that a larger num-
ber of patients, long-term follow-up, and a control group are needed
to investigate and detect a potential extra increase in spinal radio-
graphic damage due to the treatment effect of bisphosphonates on
bone formation in AS.
In conclusion, the results from this observational cohort study in
daily clinical practice show that treatment with bisphosphonates in
combination with calcium/vitamin D supplements improves BMD
over 2 years in established AS patients. Lumbar spine BMD improved
significantly, which was most pronounced in younger AS males with
limited spinal radiographic damage. Hip BMD only improved signifi-
cantly in patients also starting TNF-α inhibitors. Our finding that the
effect of treatment was most pronounced in the lumbar spine corre-
sponds to the disease process in AS since disease activity is predomi-
nantly observed in the axial skeleton.
This is the first study exploring the occurrence of radiographic
vertebral fractures in AS patients with low BMD and/or vertebral
fractures at baseline treated with bisphosphonates. Mild radiographic
vertebral fractures still occurred in postmenopausal women and
middle-aged men. Most fractures were observed in patients who
already had vertebral fractures and who were also treated withTNF-α
inhibitors because of persistent active disease. Due to the small num-
ber and differences in disease activity at baseline, it is difficult to put
the incidence rate into perspective. Since fractures are regarded as
the most important outcome of bone fragility, larger studies with
long-term follow-up are needed to further investigate the effect of
bisphosphonates and calcium/vitamin D supplements not only on
BMD but also on vertebral fractures in AS.
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Hip BMD
Z-score
−1.0 (−1.8 to −0.8) -0.8 (−1.6 to 0.0) .007
25OHvitD
(nmol/L)
38 (29 to 70) 58 (46 to 66) .726




5.8 (5.0 to 8.0) 2.2 (1.0 to 6.2) .014




14.2 (3.4 to 33.7) 15.8 (4.5 to 34.8) .042
Patients on conventional treatment (n = 9)
LS BMD
Z-score
−1.6 (−2.8 to 0.0) −1.1 (−2.3 to 0.9) .011
Hip BMD
Z-score
−1.0 (−1.5 to 0.1) −0.9 (−1.2 to 0.0) .609
25OHvitD
(nmol/L)
89 (55 to 96) 69 (52 to 88) .686




3.8 (1.9 to 5.5) 2.8 (1.8 to 4.7) .141




5.2 (1.6 to 63.2) 6.4 (2.0 to 63.2) .180
SeeTable 1 for abbreviations.
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